X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: $73.3 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2021
Details:
Under the agreement, AstraZeneca will provide research funding and Proteros will be eligible for success-based research, development, and commercial milestone payments up to 62 million EUR plus tiered royalties on annual net sales.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 26, 2021
Details:
The partnership leverages Evotec’s proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with the integrated data analysis platform PanHunter.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 22, 2021
Details:
The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
